NEW YORK, NY / ACCESSWIRE / August 15, 2021 / Pomerantz LLP is investigating claims on behalf of investors of Elanco Animal Health Incorporated (“Elanco” or the “Company”) (NYSE:ELAN). Such investors are advised to contact Robert S. Willoughby at email@example.com 888-476-6529, ext. 7980.
The investigation concerns whether Elanco and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On August 9, 2021, Elanco issued a press release reporting its financial results for the second quarter of 2021. Among other items, Elanco lowered its adjusted EPS forecast to $0.97 – $1.03, down from the previous guidance of $1.00 to $1.06. In addition, Elanco disclosed receipt of a U.S. Securities and Exchange Commission subpoena regarding its channel inventory and sales practices before mid-2020. On this news, Elanco’s stock price fell sharply during intraday trading on August 9, 2021.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class. See www.pomerantzlaw.com.
SOURCE: Pomerantz LLP
View source version on accesswire.com: